SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst significant market volatility, fueled by discussions surrounding former President Trump's public statements on geopolitical issues, including Greenland and proposed tariffs, which are sparking international concern and market reactions. Community chatter is highly polarized, with supporters pointing to a new digital token initiative as a potential short squeeze catalyst, while critics link the former President's rhetoric to broader market instability and question the stock's underlying value.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is seeing significant downward pressure driven by market apprehension surrounding Donald Trump's extended and often incoherent public address, where his discussion of tariffs and Greenland policy raises concerns about global trade stability. Community sentiment is deeply divided, with many expressing alarm over potential economic repercussions while a subset anticipates a swift "buy the dip" recovery from the current volatility.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amidst a persistent downtrend, causing frustration among some investors profiting from puts, while others aggressively "buy the dip" citing historically oversold conditions. This comes ahead of its anticipated strong December-quarter earnings, with bulls expecting robust iPhone demand and new AI partnerships with Google Gemini, despite ongoing concerns about memory chip costs and broader geopolitical trade tensions.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top trending stock as the market eagerly anticipates its highly contested earnings report, driving sharply divided community sentiment. Its recent all-cash bid for Warner Bros. Discovery assets is a major talking point, adding a complex layer to discussions around its growth trajectory. Amidst broader market volatility, many are actively debating if Netflix's streaming business makes it a 'tariff-proof' play.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently trending due to impressive positive data from its Phase 1 clinical trial of soquelitinib for atopic dermatitis, showcasing significant efficacy and a favorable safety profile. This has ignited strong bullish sentiment and a substantial surge in its share price, as the community discusses the drug's potential as a game-changer in a large and growing market. Amid the excitement, investors are actively debating the prospect of future capital raises to fund ongoing development, contrasting with confidence in the company's long-term value and potential for partnerships.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending amid heightened global trade tensions driven by discussions surrounding new tariffs and geopolitical events, notably the Greenland situation, compounded by concerns over a global bond market sell-off. Community sentiment is sharply divided, with many anticipating further weakness for technology and growth stocks, while others view current price action as an overreaction and a 'buy the dip' opportunity, often tied to expectations of a market rebound or perceived market resilience.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing a surge in attention following a pivotal FDA meeting for its ANKTIVA bladder cancer treatment, where regulators reportedly indicated no requirement for new clinical trials and requested additional data for submission within 30 days. This news has ignited strong community discussion, with investors buzzing about a potential short squeeze and highlighting ANKTIVA's broad therapeutic promise across various cancer indications. The stock's robust performance amid a challenging market is drawing significant interest, as many anticipate further positive developments and substantial long-term growth for this biotech company.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. (CRML) is drawing significant attention amidst escalating geopolitical discussions surrounding Greenland's critical rare earth deposits, with community members closely tracking potential US involvement and the company's strategic role in Western supply chains. Investors are eagerly anticipating CRML's upcoming business update call, widely viewed as a potential catalyst for further project clarity and financing news. Despite recent price volatility, many perceive current dips as accumulation opportunities, fueled by strong conviction in the company's long-term potential in the burgeoning critical minerals sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently a major topic due to mounting geopolitical tariff threats and widespread anticipation of its upcoming earnings report, with many community members expressing concern over potentially "disastrous" results. Investors are actively debating the stock's valuation, questioning its Full Self-Driving advancements, and observing increasing competition within a saturating global EV market.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending following a significant non-exclusive licensing agreement with Pfizer for its Matrix-M adjuvant technology, widely seen by the community as a validation of its core platform. This development has fueled expectations of further partnerships and a potential short squeeze, with many closely watching how management addresses continued activist investor pressure for enhanced shareholder value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revelation Biosciences, Inc. (REVB) on Tuesday announced positive safety and activity data from an early-stage trial of its investigational drug Gemini in stage 3 and 4 chronic kidney disease patients.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.revbiosciences.com/press-releases/revelation-biosciences-announces-groundbreaking-top-line-results-from-prime-clinical-study">trial </a>enrolled 40 patients aged 32 to 78 years. Different patients were treated at four different doses to evaluate the safety of Gemini, Revelation’s formulation of phosphorylated hexaacyl disaccharide, which aims to trigger the innate immune system to release pro-inflammatory cytokines and stimulate immune cell responses. Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli, the company said.However, shares of the company tumbled 17% at the time of writing, after the company reported that three severe adverse events were identified at the highest dose of Gemini in the study, including chills, nausea, and vomiting. However, this was all resolved in three hours or less, the company noted, while adding that other reported adverse events were either mild or moderate.On Stocktwits, retail sentiment around <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.revbiosciences.com/press-releases/revelation-biosciences-announces-groundbreaking-top-line-results-from-prime-clinical-study">REVB stock</a> jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.&nbsp;<figure class="image"><img style="aspect-ratio:623/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_12_24_31_PM_png_d57363a4a3.webp" alt="REVB's Sentiment Meter and Message Volume as of 12:20 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="623" height="61"><figcaption>REVB's Sentiment Meter and Message Volume as of 12:20 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user termed the news as “clear bullish” and opined that the stock could explode at any moment.<stembedurl>https://stocktwits.com/hassan101/message/627968361</stembedurl>Another user expressed surprise at the stock drop.<stembedurl>https://stocktwits.com/Chickendinner1/message/627961173</stembedurl>Revelation CEO James Rolke said that the results of the study demonstrate the potential of Gemini to be a “game-changer” in the treatment of acute and chronic inflammation. The company is now looking forward to a meeting with the FDA later this year to discuss the program's advancement, he added.Chronic kidney disease is caused by chronic inflammation. Progression of chronic kidney damage often leads to end-stage renal disease with the need for dialysis or transplantation, the company noted.REVB stock is down by about 89% this year and by about 94% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-expects-tesla-q3-deliveries-to-exceed-wall-street-estimates-but-sees-full-year-numbers-slip/chwK7ojRdtl">Gary Black Expects Tesla Q3 Deliveries To Exceed Wall Street Estimates But Sees Full-Year Numbers Slip: Retail’s Divided On Stock Performance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug

The firm also reported that Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli.

Equity

The firm also reported that Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli.


Shares of Revelation Biosciences fell 12.4% in after-hours trading Tuesday after the company said that it would be conducting a 1-for-3 reverse stock split.&nbsp;The split is expected to be effective before the market opens on July 7.&nbsp;Revelation plans to conduct the reverse split to meet Nasdaq's minimum bid requirement.The reverse split, approved at a special shareholder meeting held on June 23, will affect all outstanding shares and adjust related equity instruments, including options, warrants, and restricted stock units (RSUs).&nbsp;Revelation will retain its current ticker symbol “REVB.”Separately, Revelation stated that enrollment is expected to conclude this month in its Phase 1b trial evaluating Gemini in patients with chronic kidney disease.&nbsp;Topline results are expected soon after.Earlier this year, the company said that Gemini reduced inflammation in lab tests involving human immune cells.&nbsp;Cells primed with Gemini showed lower levels of proinflammatory cytokines and higher levels of protective anti-inflammatory markers when exposed to known inflammation triggers, including HMGB-1 and bacterial LPS.&nbsp;The company said that similar effects could be observed in patients, supporting Gemini’s potential in treating inflammation-driven conditions.On Stocktwits, retail sentiment was ‘neutral’ amid ‘low’ message volume.One user described the 1-for-3 reverse split as “small” and suggested that good news could follow shortly.&nbsp;<stembedurl>https://stocktwits.com/SkyLonger/message/619658091</stembedurl>Another user acknowledged the initial panic-driven selloff but argued the situation was different from typical reverse split moves, adding that “bigger news” may be on the way.<stembedurl>https://stocktwits.com/lookgoodplaygood22/message/619658026</stembedurl>Revelation’s stock has declined 92.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’

Shares of Revelation Biosciences fell 12.4% in after-hours trading Tuesday after the company said that it would be conducting a 1-for-3 reverse stock split. 

The company is nearing completion of enrollment in its Phase 1b Gemini trial for CKD, with topline results expected shortly. 

FTSE 100 today: BoE rate decision looms; Vodafone names CFO; Whitbread reports

Investing.com -- British stocks opened lower on Thursday as investors looked ahead to the Bank of England’s rate decision, with markets broadly anticipating no change in interest rates at the meeting.

Frasers Group decides not to make offer for Revolution Beauty

Investing.com -- Frasers Group PLC (LON:FRAS) said on Thursday that it will not make an offer for a U.K.-based cosmetics and skincare retailer   Revolution Beauty Group   PLC (LON:REVB).

Frasers explores potential bid for Revolution Beauty, company confirms

The biotech sector is already buzzing with retail investor interest as the new year begins. Here’s a look at the top three biotech stocks driving conversations on Stocktwits based on message volume jumps on the first trading day of 2025:Carmell Corp (CTCX): +58,100% Message VolumeRegenerative medicine biotech Carmell Corp surged into the spotlight after announcing an acquisition deal with PMGC Holdings’ Elevai Skincare subsidiary. The transaction includes $1.1 million in Carmell stock, $57,000 in cash, and contingent earnouts linked to Elevai’s product sales and revenue milestones.&nbsp;Carmell expects to acquire Elevai’s skincare and haircare portfolio, including a commercial team and inventory with $2.5 million in trailing revenue.&nbsp;Shares rocketed 148% on Thursday but saw some profit-taking early on Friday. Carmell’s stock lost roughly 80% last year.Mustang Bio (MBIO): +27,200% Message VolumeMustang Bio shares climbed 18% on Thursday and gained further in Friday’s pre-market, despite no apparent catalyst.&nbsp;In November, the company secured an extension from Nasdaq to meet compliance requirements and received FDA Orphan Drug Designation for MB-108, an oncolytic virus treatment for malignant glioma.&nbsp;While the stock fell nearly 85% in 2024, recent developments have sparked renewed optimism among investors.Revelation Biosciences (REVB): +9,150% Message VolumeRevelation Biosciences rose 42% on Thursday before sliding in Friday’s pre-market session without any catalyst.&nbsp;Retail buzz centers on its investigational therapy, Gemini, which received FDA clearance last month for a Phase 1b trial targeting chronic kidney disease patients.&nbsp;However, concerns around the company’s cash burn and financing moves have tempered investor enthusiasm. REVB shares dropped over 90% in 2024, leaving the stock a speculative favorite entering 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off

From acquisition news and FDA designations to fresh optimism for struggling stocks, these biotechs piqued Stocktwits users the most on the first trading day of 2025.

European stock markets slip lower; manufacturing activity data in spotlight

The headline HCOB Spain Manufacturing Purchasing Managers' Index rose to 53.3 in December from 53.1 in November, marking the 11th consecutive month above the 50.0 threshold that indicates growth.

Revolution Beauty settles Chrysalis dispute, shares jump 13% in early trading

Revelation Biosciences Inc. (REVB), a nano-cap biopharmaceutical company, has captured the attention of retail investors in a big way.On Wednesday, REVB saw the highest jump in new retail watchers on Stocktwits, with its following increasing by a staggering 8.79%, as shares doubled in value and became one of the top gainers on U.S. stock exchanges. &nbsp;The surge in interest stems from Revelation's recent success in a Phase 1 clinical trial for Gemini, its proprietary immune preconditioning therapy.The trial confirmed the safety and effectiveness of escalating doses of Gemini, while also showcasing significant, dose-dependent changes in biomarkers indicative of the drug's ability to stimulate the immune system. &nbsp;Encouraged by these results, Revelation CEO James Rolke announced plans to rapidly move forward with a Phase 1b study involving patients later in 2024.Gemini is being developed as a single-dose pre-treatment for two specific purposes: to prevent or reduce the severity of acute kidney injury (AKI) in patients undergoing cardiac surgery; and reduce the incidence, duration, and severity of post-surgical infections.<stembedurl>https://stocktwits.com/Jay_Investor/message/583783850</stembedurl>The positive clinical trial data and the upcoming Phase 1b study have fueled an ‘extremely bullish’ sentiment (89/100) on Stocktwits, with message volume soaring by a remarkable 4,427% over the past 24 hours on Wednesday.<figure class="image"><a href="https://stocktwits.com/symbol/REVB"><img style="aspect-ratio:1320/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/REVB_sentiment_and_message_volume_Aug_22_9c91f8f659.png" alt="REVB sentiment and message volume Aug 22.png" width="1320" height="318"></a><figcaption>REVB sentiment and message volume Aug 22</figcaption></figure>While REVB was among the top gainers in the previous session, it tumbled by 31% on Thursday after the company announced exercising warrants to purchase additional shares at a reduced price.&nbsp;&nbsp;

The surge in interest stems from Revelation's recent success in a Phase 1 clinical trial for Gemini, its proprietary immune preconditioning therapy. 

Revelation Biosciences Stock: Retail Interest Soars After Positive Trial Results

Investor sentiment on Stocktwits is ‘extremely bullish’ due to positive Phase 1 clinical trial results for its immune preconditioning therapy.

Investor sentiment on Stocktwits is ‘extremely bullish’ due to positive Phase 1 clinical trial results for its immune preconditioning therapy. The company is planning a Phase 1b study with patients later in 2024


Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

Revelation Biosciences Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

REVB
Revelation Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest REVB News

REVBRevelation Biosciences Inc